Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.sekisuidiagnostics.com
Global Number of Employees (Latest): 450
Year Founded: 1981
Total Amount Raised (CAD mm)†: 2.56
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Sekisui Diagnostics, LLC. manufactures and distributes clinical chemistry products, such as routine and specialty tests, and compact chemistry systems; coagulation systems, blood collection tubes, and specialty reagents/assays that supports clinical testing; infectious disease tests in multiple formats, human genetics, traded products, and instrumentation; OSOM rapid diagnostic products for point-of-care testing; and specialty biochemicals and enzymes for diagnostic reagent and biosensor manufacturers. Its products are used for anemia, cardiovascular, diabetes, immunology, infectious disease, kidney disease, liver disease, metabolic disorder, novel markers, pancreatitis, and toxicology diagnostic needs. It sells its products directly in the United States and Germany; and through sales and distribution network internationally. The company was formerly known as Genzyme Diagnostics, Inc. and changed its name to Sekisui Diagnostics, LLC. in February 2011. The company was founded in 1981 and is based in Burlington, Massachusetts with additional offices in San Diego, California; Stamford, Connecticut; Exton, Pennsylvania; Charlottetown, Canada; Kent, United Kingdom; and Rüsselshiem and Pfungstadt, Germany. As of February 1, 2011, Sekisui Diagnostics, LLC. operates as a subsidiary of Sekisui Medical CO., Ltd.


Financial Information (Currency: CAD, in mm)
Total Revenue
 188.6
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
 450
Net Debt
-
U.S. Number of Employees 2021
 263
U.S. Number of Employees 2020
 261
U.S. Last Year Employee Growth %
 0.8
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Schruender, Bob 
President & CEO
Bauer, Alan
Vice President of Global Finance
Turner, Lisa 
Director of Marketing Communications


Primary Industry Classification
Health Care Equipment


Primary Office Location
One Wall Street | Burlington, MA | 01803 | United States
Phone: 781 652 7800   Fax: 800 762 6311

Parent Company
Sekisui Medical Co., Ltd.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
American Diagnostica Inc.
As of March 23, 2009, American Diagnostica Inc. was acquired by Sekisui America Corporation. American Diagnostica Inc. discovers, develops, manufactures, and distributes clinical diagnostic and research products for use in the fields of coagulation, fibrinolysis, thrombosis, hemostasis, and oncology. Its products include clinical diagnostic and research assays, control plasma and sera products, proteins, antibodies and antisera products, chromogenic and fluorogenic substrates, protease inhibitors, snake venom protease activators, and special collection tubes for blood. The company sells its products through distributors to hospitals, medical testing laboratories, university research facilities, and pharmaceutical companies in the United States and internationally. It also serves the clinical diagnostic, biopharmaceutical, and life science research markets. American Diagnostica Inc. was founded in 1982 and is based in Stamford, Connecticut. It has sales offices in the United States, Canada, France, and Germany. It operates manufacturing and research facilities in Stamford, Connecticut; and additional research laboratories in Montréal, Canada; and Pfungstadt, Germany.

United States and Canada
Health Care Equipment
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-14-2019
May-14-2019
Private Placement
Target
Sekisui Diagnostics, LLC.


1.90
Nov-11-2016
-
Merger/Acquisition
Seller
Sekisui Virotech GmbH (nka:VIROTECH Diagnostics GmbH)
Pangea Unternehmerkapital GmbH
Sekisui Diagnostics, LLC.
-
Nov-18-2010
Feb-1-2011
Merger/Acquisition
Target
Genzyme Diagnostics, Inc. (nka:Sekisui Diagnostics, LLC.)
Sekisui Medical Co., Ltd.
Genzyme Corporation Inc
265.00
Jul-1-1999
Jul-1-1999
Merger/Acquisition
Seller
Genzyme Diagnostics, Bioreagent and ELISA Immunochemistry Product Lines
Alexon Trend, Inc.
Genzyme Diagnostics, Inc. (nka:Sekisui Diagnostics, LLC.)
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-31-2023
Product-Related Announcements
SEKISUI Diagnostics Announces the Launch of the OSOM COVID-19 Antigen Home Test
Nov-17-2020
Product-Related Announcements
SEKISUI Diagnostics Announces Launch of the OSOM Ultra Plus Flu A&B Test in Europe
Jul-29-2020
Business Expansions
Sekisui Diagnostics Invests £14.4 Million in cGMP Biopharma CDMO Capacity
Mar-23-2020
Client Announcements
Sekisui Diagnostics Enters into Distribution Agreement with Mesa Biotech
Nov-25-2019
Business Expansions
Sekisui Diagnostics Opens $1.9 Million Bioprocess Innovation Centre

Competitors
Beckman Coulter, Inc., Becton, Dickinson and Company (NYSE:BDX)

M&A Advisors
Lincoln International AG


Advisors
M&A Advisors
Lincoln International AG


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 07:03 PM
Sekisui Diagnostics, LLC.
Sekisui Diagnostics LLC
Reports
36
GlobalData

Jun 14, 2023 11:39 PM
Sekisui Diagnostics, LLC.
Sekisui Diagnostics LLC
Reports
38
GlobalData

Mar 13, 2023 11:29 PM
Sekisui Diagnostics, LLC.
Sekisui Diagnostics LLC
Reports
38
GlobalData

Dec 14, 2022 11:17 PM
Sekisui Diagnostics, LLC.
Sekisui Diagnostics LLC
Reports
39
GlobalData

Oct 27, 2022 07:30 AM
Sekisui Diagnostics, LLC.
Sekisui Diagnostics LLC - Medical Equipment - Deals and Alliances Profile
Reports
19
GlobalData

Sep 23, 2022 02:34 AM
Sekisui Diagnostics, LLC.
Sekisui Diagnostics LLC
Reports
39
GlobalData

Jul 20, 2022 01:34 AM
Sekisui Diagnostics, LLC.
Sekisui Diagnostics LLC - Medical Equipment - Deals and Alliances Profile
Reports
19
GlobalData

Jun 15, 2022 10:42 PM
Sekisui Diagnostics, LLC.
Sekisui Diagnostics LLC
Reports
39
GlobalData

May 23, 2022 06:00 AM
Sekisui Diagnostics, LLC.
Sekisui Diagnostics LLC - Medical Equipment - Deals and Alliances Profile
Reports
19
The Insight Partners
The Insight Partners Research Team
Mar 25, 2022 05:35 AM
Sekisui Diagnostics, LLC.
Sekisui Diagnostics in Global Acetaminophen Reagents Market
Notes
5


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
OSOM BVBLUE Test, SEKURE HbA1c Assay

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Schruender, Bob 
President & CEO
781 652 7800
800 762 6311
-
Bauer, Alan
Vice President of Global Finance
781 652 7800
800 762 6311
-
Turner, Lisa 
Director of Marketing Communications
(858) 777-2660
800 762 6311
lisa.turner@sekisui-dx.com
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
